Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Cellular engineering for genetic diseases and cancer
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-Cas12b
Funding stage: Public (NASDAQ:SANA)
Location: Seattle, Washington, United States
Partners: Beam Therapeutics
Sana Biotechnology is a Seattle-based company that focuses on the development of in vivo and ex vivo engineered cell therapies. Using its Fusogen technology platform, the company aims to create in vivo engineered CAR-T cells, which might circumvent many of the obstacles associated with conventional CAR-T cell therapies. Likewise, the company's Hypoimmune technology is being applied for the development of ex vivo engineered donor- and stem cell-derived cellular therapies. The company has obtained licenses from Beam Therapeutics to use the CRISPR-Cas12b system as part of a number of its ex vivo engineered cell programmes.